KRYS - Cantor starts Krystal Biotech at overweight cites Vyjuvek launch
2023-10-25 19:00:31 ET
More on Krystal Biotech
- Krystal Biotech: FDA Approval Of Vyjuvek And Further Pipeline Enhancement
- Krystal Biotech: Pioneering Rare Disease Gene Therapies
- Krystal Biotech wins FDA nod to run trial for gene therapy
- Berenberg starts Krystal Biotech at buy, cites upcoming drug launch
- Seeking Alpha’s Quant Rating on Krystal Biotech
For further details see:
Cantor starts Krystal Biotech at overweight, cites Vyjuvek launch